<DOC>
	<DOC>NCT00961909</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled study will assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of RO5095932 in patients with type 2 diabetes mellitus. Patients will be randomized to receive either RO5095932 subcutaneously once weekly or placebo for 4 weeks (part 1) or 6 weeks (part 2), in addition to their current stable doses of metformin.</brief_summary>
	<brief_title>A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>adult patients, 1865 years of age females who are either surgically sterile or postmenopausal type 2 diabetes treated with a stable dose of metformin BMI between 2539kg/m2 HbA1c between 7 and 10% fasting plasma glucose between 7 and 13.3mmol/L history of clinically significant cardiovascular disease history of clinically significant hepatic or renal disease or impairment recent therapy with insulin, thiazolidinedione, glucagonlike peptide1 analogues, amylin analogues and/or DPPIV inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>